NCT06531486

A Study of XS-02 Capsules in Patients With Advanced Solid Tumors

A Multicenter, Open Label, Single-arm Phase I/II Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Initial Efficacy of XS-02 Capsules in Patients With Advanced Solid Tumors

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 96 (estimated)
• Sponsor: NovaOnco Therapeutics Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A study to evaluate the safety, tolerability, Pharmacokinetics(pk), and efficacy of XS-02 capsules in patients with advanced solid tumors.

Detailed description

This is a multicenter, open label, single-arm Phase I/II dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic profile, and initial efficacy of XS-02 capsules in patients with advanced solid tumors.

Conditions

• Solid Tumor
• Ovarian Cancer
• Breast Cancer
• Endometrial Cancer

Interventions

Type	Name	Description
OTHER	XS-02 capsules	Upon completion of all screening visits, eligible patients will be treated with XS-02 capsules at the appropriate dose.

Timeline

• Start date: 2024-07-29
• Primary completion: 2027-02-28
• Completion: 2027-08-30
• First posted: 2024-08-01
• Last updated: 2024-08-01